A. Dudek

发表

Containers for freezing and storage of bone marrow stem cells.

M. Červinka, P. Měřička, P. Schustr, 1991, Sbornik vedeckych praci Lekarske fakulty Karlovy university v Hradci Kralove.

Serotype transmission dynamics and reduced incidence of invasive pneumococcal disease caused by different serotypes after implementation of non-pharmaceutical interventions during COVID-19 pandemic

C. Chiu, Chyi-Liang Chen, L. Su, 2021, The European respiratory journal.

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

F. Ariel, P. Rahman, E. Lee, 2019, The Lancet.

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

R. Moots, P. Emery, D. Mevorach, 2017, The Lancet.

MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16

H. Bliddal, J. Bijlsma, M. Østergaard, 2014, Annals of the rheumatic diseases.

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

L. Coates, D. Gladman, Pille Harrison, 2018, The Lancet.

The influence of Sm-153 therapy on bone marrow function

B. Małkowski, M. Wedrowski, A. Dudek, 2016, Contemporary oncology.

d-mannose-sensitive pilus of Acinetobacter baumannii is linked to biofilm formation and adherence onto respiratory tract epithelial cells.

C. Chiu, Han-Yueh Kuo, Hao-Yuan Lee, 2021, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis: results from a randomised, placebo-controlled, phase 2 trial (EQUATOR)

L. Coates, D. Gladman, Pille Harrison, 2019 .

FRI0246 Magnetic Resonance Imaging-Assessment of Early Response to Certolizumab Pegol in Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled Phase Iiib Study Applying Magnetic Resonance Imaging at Weeks 0, 1, 2, 4, 8 and 16

L. Jacobsson, H. Bliddal, J. Bijlsma, 2014 .

[Coexistence of pulmonary sequestration and congenital cystic adenomatoid malformation. Case report and review of literature].

M. Kulus, K. Krenke, A. Dudek, 2014, Pneumonologia i alergologia polska.

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and

M. Dougados, J. Reveille, R. Landewé, 2018, The Lancet.

Thomsen-Friedenreich antigen activation as a predictor for clinical outcome of pediatric patients with invasive pneumococcal disease.

C. Chiu, Chyi-Liang Chen, A. Dudek, 2020, Pediatrics and neonatology.

SAT0089 SAFETY AND EFFICACY OF LY3337641, A BRUTON’S TYROSINE KINASE INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART PHASE 2 STUDY

M. Genovese, W. Park, A. Kivitz, 2019, SATURDAY, 15 JUNE 2019.

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

D. Furst, E. Keystone, P. Klimiuk, 2021, Arthritis Research & Therapy.

Marine prebiotics mediate decolonization of Pseudomonas aeruginosa from gut by inhibiting secreted virulence factor interactions with mucins and enriching Bacteroides population

Yuan-Ming Yeh, Yuan-chuan Lee, K. Chien, 2023, Journal of Biomedical Science.

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

M. Weinblatt, E. Keystone, S. de Bono, 2017, Annals of the rheumatic diseases.

Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis

D. Furst, P. Klimiuk, J. Kay, 2021, Rheumatology.

ORIGINAL ARTICLE Chronic viral hepatitis as the cause of arthritis

A. Bachta, A. Dudek, M. Tłustochowicz, 2006 .

Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study

J. Reveille, A. Deodhar, K. Lo, 2019, The Journal of Rheumatology.

Functional characterization and clinical implication of a novel epidemic carbapenem-resistant Acinetobacter baumannii genetic marker.

Hao-Yuan Lee, Chyi-Liang Chen, A. Dudek, 2023, International journal of antimicrobial agents.

Safety and Efficacy of Poseltinib, Bruton’s Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study

M. Genovese, W. Park, A. Kivitz, 2020, The Journal of Rheumatology.

Recognition factors of Dolichos biflorus agglutinin (DBA) and their accommodation sites

A. M. Wu, A. Dudek, Y. Chen, 2023, Glycoconjugate Journal.